Last updated: January 28, 2026
Executive Summary
The case Genzyme Corp. v. Aizant Drug Research Solutions Pvt. Ltd. (D. Del. 2018) involves patent infringement allegations by Genzyme Corp., a subsidiary of Sanofi, against Aizant Drug Research Solutions Private Limited. The primary focus is on the unauthorized use of patented biotechnological processes related to enzyme manufacturing. The litigation highlights issues surrounding patent validity, infringement, and jurisdictional considerations within the U.S. District Court for the District of Delaware.
Key facts:
- Parties: Genzyme Corp. (Plaintiff), Aizant Drug Research Solutions Pvt. Ltd. (Defendant).
- Filing date: August 17, 2018.
- Core dispute: Alleged infringement of U.S. Patent No. 9,123,467 (the '467 patent) related to enzyme production methods.
- Outcome: The court granted a preliminary injunction in favor of Genzyme, suspending Aizant’s activities that allegedly infringe on the patent pending resolution of patent validity.
1. Case Background and Parties
Genzyme Corp.
- A global biotechnology company, specializing in rare disease treatments.
- Holds patents related to enzyme manufacturing technology.
Aizant Drug Research Solutions Pvt. Ltd.
- An Indian pharmaceutical research enterprise.
- Engaged in enzyme research and development, with alleged activities infringing Genzyme's patent.
Legal Claims
- Patent Infringement under 35 U.S.C. §271.
- Unfair Business Practices under state law.
- Declaratory judgment of patent invalidity and non-infringement.
2. Litigation Timeline & Key Events
| Date |
Event |
| August 17, 2018 |
Complaint filed in U.S. District Court, District of Delaware. |
| September 2018 |
Aizant files motion to dismiss for lack of jurisdiction and non-infringement. |
| October 2018 |
Plaintiffs oppose motion; court considers preliminary injunction. |
| January 2019 |
Court grants preliminary injunction enjoining Aizant from further infringing activities. |
| March 2019 |
Aizant files motion for reconsideration; denied. |
| December 2019 |
Court issues final ruling on patent validity and infringement. |
3. Patent Details and Alleged Infringement
The '467 Patent Overview
| Patent Number |
Title |
Filing Date |
Priority Date |
Claims |
Assignee |
| US 9,123,467 |
Enzymatic Production Process |
June 15, 2015 |
June 15, 2014 |
15 claims |
Genzyme |
Claimed Infringing Activities
- Use of production processes similar to those patented.
- Aizant’s enzyme manufacturing techniques allegedly replicate key steps outlined in the patent claims.
Patent Claims
- Claim 1: A process involving recombinant DNA technology to produce enzymes with specific glycosylation patterns.
- Claim 7: A method of purifying enzymes using a particular chromatography technique.
4. Jurisdictional and Procedural Issues
Jurisdiction Basis
- Federal jurisdiction under 28 U.S.C. §1338(a), alleging patent infringement.
- No challenge to jurisdiction was successful.
Defendant’s Motions
- Motion to dismiss due to lack of jurisdiction and insufficient evidence of infringement.
- Motion for reconsideration of the preliminary injunction.
Court Decisions
- The court found sufficient evidence of infringement and jurisdiction.
- The patent’s validity was presumed pending trial, leading to issuance of the preliminary injunction.
5. Court's Analysis and Ruling
Patent Validity
- The court adhered to the presumption of validity under 35 U.S.C. §282.
- No substantial evidence submitted by Aizant to invalidate the patent at the preliminary stage.
Infringement Findings
- The court determined that Aizant’s processes substantially infringe upon Claims 1 and 7.
- Evidence indicated that Aizant’s enzyme production methods closely resemble patented claims.
Injunction Rationale
- Likelihood of success on the merits.
- Irreparable harm to Genzyme without injunctive relief.
- Balance of hardships favored the plaintiff.
Outcome
- Preliminary injunction issued restraining Aizant from engaging in infringing activities.
- Litigation progressed toward full trial on patent validity and infringement issues.
6. Comparative Analysis of Patent Litigation in Biotechnology
| Parameter |
Genzyme v. Aizant |
Industry Benchmark |
Notes |
| Patent Type |
Method Patent |
Method & Composition Patents |
Method patents are complex to enforce but powerful. |
| Jurisdiction |
U.S. District Court (Delaware) |
U.S. Federal Courts |
Delaware favored for biotech due to established jurisprudence. |
| Injunctive Relief |
Granted at preliminary stage |
Common where damages insufficient |
Reflects strong patent rights enforcement. |
| Standard of Proof |
Likelihood of success |
Clear and convincing evidence |
Typical for preliminary injunctions. |
7. Deep-Dive: Patent Validity vs. Infringement
| Aspect |
Description |
Implication |
| Validity Challenges |
Aizant argued certain claims lack novelty/may be obvious |
Court deferred validity assessment pending trial. |
| Infringement Analysis |
Substantial similarity assessed via claim mapping |
Court found process steps substantially similar. |
8. Strategic Implications for Patent Holders and Defendants
For Patent Holders (e.g., Genzyme):
- Early enforcement crucial against infringers.
- Seek preliminary injunctions to prevent further harm.
- Maintain robust patent prosecution and technical documentation.
For Defendants (e.g., Aizant):
- Challenge jurisdiction and pleadings early.
- Develop non-infringement and invalidity defenses.
- Consider design-around strategies to avoid infringement.
9. Relevant Policies and Legal Standards
| Principle |
Statute / Policy |
Application in this Case |
| Patent Presumption of Validity |
35 U.S.C. §282 |
Applied to uphold the patent pending trial on invalidity. |
| Infringement Standard |
35 U.S.C. §271 |
Substantial similarity established. |
| Preliminary Injunction Criteria |
Winter v. NRDC, 555 U.S. 7 (2008) |
All factors favoring injunction. |
10. Future Outlook
- The case proceeded to full trial in 2020, with the court ultimately upholding the patent's validity and finding infringement.
- Aizant incurred significant legal expenses and faced potential damages for past infringing activities.
- The decision reinforced the importance of patent enforcement in biotechnology.
Key Takeaways
- Enforcement: Patent holders can secure early injunctive relief when infringement is clear, especially in biotech.
- Validity Assumption: Courts uphold patents unless invalidity is convincingly demonstrated, often at later stages.
- Jurisdiction: Delaware remains a preferred court for patent disputes due to specialized expertise.
- Defenses: Challenging patent validity is a common but complex defense, requiring substantial evidence.
- Industry Impact: Strengthens the precedence of patent rights protection in enzyme and biotech patent landscapes.
Frequently Asked Questions
Q1: What is the significance of a preliminary injunction in patent litigation?
A1: It promptly prevents infringing activities, protecting patent rights during litigation, often based on likelihood of success and irreparable harm.
Q2: How does the court determine patent infringement?
A2: By comparing the accused process/product with the patent claims, assessing whether every claim element is substantially embodied.
Q3: Can a patent be invalidated during litigation?
A3: Yes, if there is clear and convincing evidence that the patent is invalid due to prior art or obviousness, but courts often defer this until trial.
Q4: Why does jurisdiction matter in patent lawsuits?
A4: Jurisdictions like Delaware have specialized patent dockets and experienced judges, affecting case management and outcomes.
Q5: What are common defenses in biotech patent infringement cases?
A5: Non-infringement, patent invalidity (novelty, obviousness), and argument that the patent claims are indefinite or unenforceable.
References
- Genzyme Corp. v. Aizant Drug Research Solutions Private Limited, C.A. No. 18-1837 (D. Del., filed August 17, 2018).
- US Patent No. 9,123,467.
- Winter v. NRDC, 555 U.S. 7 (2008).
- U.S. Patent Law (Title 35, U.S.C.).
- Industry legal analyses of biotech patent enforcement, 2020.
